[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BRPI0519280A2 - composto, composiÇço farmacÊutica e uso de um composto - Google Patents

composto, composiÇço farmacÊutica e uso de um composto

Info

Publication number
BRPI0519280A2
BRPI0519280A2 BRPI0519280-3A BRPI0519280A BRPI0519280A2 BR PI0519280 A2 BRPI0519280 A2 BR PI0519280A2 BR PI0519280 A BRPI0519280 A BR PI0519280A BR PI0519280 A2 BRPI0519280 A2 BR PI0519280A2
Authority
BR
Brazil
Prior art keywords
compound
pharmaceutical composition
compounds
relates
pharmaceutical compositions
Prior art date
Application number
BRPI0519280-3A
Other languages
English (en)
Inventor
Anja Fecher
Heinz Fretz
Markus Riederer
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of BRPI0519280A2 publication Critical patent/BRPI0519280A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/86—Carbazoles; Hydrogenated carbazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

COMPOSTO, COMPOSIÇçO FARMACÊUTICA E USO DE UM COMPOSTO. A invenção diz respeito aos novos derivados de tetraidro-1H- carbazol e seus usos como ingredientes ativos na preparação de composições farmacêuticas. A invenção também diz respeito aos aspectos relacionados incluindo os processos para a preparação dos compostos, as composições farmacêuticas contendo um ou mais destes compostos e aos métodos de tratamento compreendendo a administração dos ditos compostos aos pacientes.
BRPI0519280-3A 2004-12-27 2005-12-22 composto, composiÇço farmacÊutica e uso de um composto BRPI0519280A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2004014719 2004-12-27
PCT/IB2005/054380 WO2006070325A2 (en) 2004-12-27 2005-12-22 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists

Publications (1)

Publication Number Publication Date
BRPI0519280A2 true BRPI0519280A2 (pt) 2009-01-06

Family

ID=36499938

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0519280-3A BRPI0519280A2 (pt) 2004-12-27 2005-12-22 composto, composiÇço farmacÊutica e uso de um composto

Country Status (27)

Country Link
US (1) US8039474B2 (pt)
EP (1) EP1833791B1 (pt)
JP (1) JP5137240B2 (pt)
KR (1) KR101329903B1 (pt)
CN (1) CN101084190B (pt)
AR (1) AR052549A1 (pt)
AT (1) ATE518834T1 (pt)
AU (1) AU2005320964B2 (pt)
BR (1) BRPI0519280A2 (pt)
CA (1) CA2594280C (pt)
CY (1) CY1112376T1 (pt)
DK (1) DK1833791T3 (pt)
ES (1) ES2369782T3 (pt)
HK (1) HK1111698A1 (pt)
HR (1) HRP20110773T1 (pt)
IL (1) IL184233A0 (pt)
MX (1) MX2007007691A (pt)
MY (1) MY144897A (pt)
NO (1) NO20073059L (pt)
NZ (1) NZ556657A (pt)
PL (1) PL1833791T3 (pt)
PT (1) PT1833791E (pt)
RU (1) RU2404163C2 (pt)
SI (1) SI1833791T1 (pt)
TW (1) TW200633978A (pt)
WO (1) WO2006070325A2 (pt)
ZA (1) ZA200705085B (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1725553T1 (sl) 2004-03-11 2008-08-31 Actelion Pharmaceuticals Ltd Derivati tetrahidropiridoindola
KR101411820B1 (ko) 2006-08-07 2014-06-24 액테리온 파마슈티칼 리미티드 (3-아미노-1,2,3,4-테트라하이드로-9ｈ-카르바졸-9-일)-아세트산 유도체
CN101952244B (zh) 2008-02-01 2014-11-05 潘米拉制药公司 前列腺素d2受体的n，n-二取代氨基烷基联苯拮抗剂
WO2009108720A2 (en) 2008-02-25 2009-09-03 Amira Pharmaceuticals, Inc. Antagonists of prostaglandin d2 receptors
WO2010008864A2 (en) 2008-06-24 2010-01-21 Amira Pharmaceuticals, Inc. Cycloalkane[b]indole angtagonists of prostaglandin d2 receptors
GB2463788B (en) 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
WO2010039977A2 (en) 2008-10-01 2010-04-08 Amira Pharmaceuticals, Inc. Heteroaryl antagonists of prostaglandin d2 receptors
US8524748B2 (en) 2008-10-08 2013-09-03 Panmira Pharmaceuticals, Llc Heteroalkyl biphenyl antagonists of prostaglandin D2 receptors
GB2465062B (en) 2008-11-06 2011-04-13 Amira Pharmaceuticals Inc Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors
BRPI1008906B1 (pt) * 2009-02-24 2019-10-15 Merck Sharp & Dohme Corp. Composto, composição farmacêutica, e, uso de um composto
EP2461809A4 (en) 2009-07-31 2013-06-19 Panmira Pharmaceuticals Llc OPHTHALMIC PHARMACEUTICAL COMPOSITIONS OF DP2 RECEPTOR ANTAGONSITES
JP2013501052A (ja) 2009-08-05 2013-01-10 パンミラ ファーマシューティカルズ，エルエルシー． Ｄｐ２アンタゴニストおよびその用途
MY183111A (en) 2010-03-22 2021-02-15 Idorsia Pharmaceuticals Ltd 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
WO2012051036A1 (en) 2010-10-11 2012-04-19 Merck Sharp & Dohme Corp. Quinazolinone-type compounds as crth2 antagonists
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
SG193902A1 (en) 2011-04-14 2013-11-29 Actelion Pharmaceuticals Ltd 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin d2 receptor modulators
US8592383B2 (en) 2011-06-17 2013-11-26 Merck Sharp & Dohme Corp. Cycloalkyl-fused tetrahydroquinolines as CRTH2 receptor modulators
SI3119779T1 (sl) 2014-03-17 2018-10-30 Idorsia Pharmaceuticals Ltd Derivati azaindolocetne kisline in njihova uporaba kot modulatorji prostaglandinskega receptorja D2
MX2016011900A (es) 2014-03-18 2016-12-05 Actelion Pharmaceuticals Ltd Derivados de acido azaindol-acetico y su uso como moduladores del receptor de prostaglandina d2.
PL3350179T3 (pl) 2015-09-15 2021-08-02 Idorsia Pharmaceuticals Ltd Krystaliczne postacie

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687969A (en) * 1970-06-02 1972-08-29 Sterling Drug Inc 9-aroyl-1,2,3,4-tetrahydrocarbazole-3,3-dicarboxylic acids
GB1335228A (en) * 1970-06-02 1973-10-24 Sterling Drug Inc Tetrahydrocarbazoles
US3941805A (en) * 1972-11-17 1976-03-02 Sterling Drug Inc. 3-Halomethylcarbonyl-9-benzoyl-1,2,3,4-tetrahydrocarbazoles
US4808608A (en) 1986-01-23 1989-02-28 Merck & Co., Inc. Tetrahydrocarbazole 1-alkanoic acids, pharmaceutical compositions and use
US20010047027A1 (en) 2000-04-12 2001-11-29 Marc Labelle Prostaglandin D2 receptor antagonists
AU2002302248B2 (en) 2001-05-23 2008-03-06 Merck Frosst Canada Ltd. Dihydropyrrolo[1,2-A]indole and tetrahydropyrido[1,2-A]-indole derivatives as prostaglandin D2 receptor antagonists
AU2002361430B2 (en) * 2001-12-14 2007-09-13 Zentaris Gmbh Tetrahydrocarbozole derivatives as ligands for G-protein coupled receptors (GPCR)
AR038136A1 (es) 2002-01-24 2004-12-29 Merck Frosst Canada Inc Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
SE0200356D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
SE0200411D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
WO2003097042A1 (fr) 2002-05-16 2003-11-27 Shionogi & Co., Ltd. Antagoniste de recepteur de pdg2
WO2003097598A1 (fr) 2002-05-16 2003-11-27 Shionogi & Co., Ltd. Composé comprenant un antagonisme du récepteur de pdg2
GB2388540A (en) 2002-05-17 2003-11-19 Bayer Ag New use of Ramatroban
TW200307542A (en) 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
SE0201635D0 (sv) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
SE0202241D0 (sv) 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
US7618979B2 (en) 2002-10-30 2009-11-17 Merck Frosst Canada Ltd. Pyridopyrrolizine and pyridoindolizine derivatives
JPWO2004078719A1 (ja) 2003-03-06 2006-06-08 小野薬品工業株式会社 インドール誘導体化合物およびその化合物を有効成分とする薬剤
CN1791577A (zh) 2003-05-20 2006-06-21 麦克弗罗斯特加拿大有限公司 氟－甲基磺酰取代的环烷并吲哚和它们作为前列腺素d2拮抗剂的用途
SE0301569D0 (sv) 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
JP2006527205A (ja) 2003-06-12 2006-11-30 メルク フロスト カナダ リミテツド Ｄｐ受容体拮抗物質としてのシクロアルカンピロロピリジン
SE0302232D0 (sv) 2003-08-18 2003-08-18 Astrazeneca Ab Novel Compounds
WO2005040112A1 (en) 2003-10-14 2005-05-06 Oxagen Limited Compounds with pgd2 antagonist activity
CA2542716A1 (en) 2003-10-14 2005-05-06 Oxagen Limited Compounds having crth2 antagonist activity
GB2407318A (en) 2003-10-23 2005-04-27 Oxagen Ltd Substituted Indol-3-yl acetic acid derivatives
GB0324763D0 (en) 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
SE0303180D0 (sv) 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
US7019022B2 (en) 2003-12-15 2006-03-28 Merck Frosst Canada & Co. Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
DE602005014849D1 (de) 2004-01-31 2009-07-23 Actimis Pharmaceuticals Inc Imidazoä1,2-cüpyrimidinylessigsäurederivate
SI1725553T1 (sl) 2004-03-11 2008-08-31 Actelion Pharmaceuticals Ltd Derivati tetrahidropiridoindola
CA2558545C (en) 2004-03-11 2012-10-16 Actelion Pharmaceuticals Ltd Indol-1-yl-acetic acid derivatives
CN101052397B (zh) 2004-08-26 2011-07-06 埃科特莱茵药品有限公司 2-硫烷基-苯并咪唑-1-基-乙酸衍生物
KR101411820B1 (ko) 2006-08-07 2014-06-24 액테리온 파마슈티칼 리미티드 (3-아미노-1,2,3,4-테트라하이드로-9ｈ-카르바졸-9-일)-아세트산 유도체

Also Published As

Publication number Publication date
ES2369782T3 (es) 2011-12-05
HK1111698A1 (en) 2008-08-15
WO2006070325A3 (en) 2006-09-14
CA2594280C (en) 2013-04-23
JP5137240B2 (ja) 2013-02-06
WO2006070325A2 (en) 2006-07-06
DK1833791T3 (da) 2011-10-24
SI1833791T1 (sl) 2011-11-30
CN101084190A (zh) 2007-12-05
HRP20110773T1 (hr) 2011-11-30
KR20070104367A (ko) 2007-10-25
CA2594280A1 (en) 2006-07-06
PT1833791E (pt) 2011-10-19
CY1112376T1 (el) 2015-12-09
KR101329903B1 (ko) 2013-11-14
RU2404163C2 (ru) 2010-11-20
PL1833791T3 (pl) 2011-12-30
MY144897A (en) 2011-11-30
EP1833791A2 (en) 2007-09-19
EP1833791B1 (en) 2011-08-03
ZA200705085B (en) 2008-08-27
AR052549A1 (es) 2007-03-21
ATE518834T1 (de) 2011-08-15
US20090270414A1 (en) 2009-10-29
MX2007007691A (es) 2007-08-14
NZ556657A (en) 2010-10-29
JP2008525426A (ja) 2008-07-17
CN101084190B (zh) 2011-01-26
AU2005320964B2 (en) 2011-12-15
RU2007128736A (ru) 2009-02-10
IL184233A0 (en) 2007-10-31
US8039474B2 (en) 2011-10-18
TW200633978A (en) 2006-10-01
AU2005320964A1 (en) 2006-07-06
NO20073059L (no) 2007-07-19

Similar Documents

Publication Publication Date Title
BRPI0508540A8 (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI0519280A2 (pt) composto, composiÇço farmacÊutica e uso de um composto
BRPI0508263A (pt) derivados de 1, 2, 3, 4-tetra-hidro-isoquinolina, composição farmacêutica, e, uso de derivado de 1, 2, 3, 4-tetra-hidro-isoquinolina
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
NO20092529L (no) Substituerte 2,3-dihydroimidazo[1,2-c]kinazolinderivater som er anvendbare for behandling av hyperproliferative forstyrrelser og sykdommer assosiert med angiogenese
BR112013011634A2 (pt) derivados de 2,3-di-hidroimidazol[1,2-c]quinazolina substituídos por aminoálcool úteis para tratar os distúrbios hiperproliferativos e as doenças associadas com a angiogênese derivados de 2,3-di-hidroimidazol[1,2-c]
EA200901133A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
BRPI0618552B8 (pt) compostos derivados de pirimidina ligados ao oxigênio,composição farmacêutica que inclui os ditos compostos,método de síntese dos compostos e usos terapêuticos dos mesmos
BRPI0407253A (pt) Heterociclil-3-sulfonilindazóis como ligandos 5-hidroxitriptamina-6 processo de preparação dos mesmos, seus usos na preparação de uma composição farmacêutica e composição farmacêutica compreendendo os referidos compostos
BRPI0507198A (pt) derivados de bisariluréia
CU23208A3 (es) Oxazolidinonas sustituidas y su uso en el campo de la coagulacion sanguinea
CY1108794T1 (el) Σπειροκυκλικα παραγωγα κυκλοεξανιου
BRPI0607796A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, processo para preparação e uso do mesmo, e, composição farmacêutica
BR0312000A (pt) Compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, uso dos compostos
BRPI0806863B8 (pt) uso de um éster de forbol na preparação de um medicamento para prevenção ou tratamento de uma infecção por hiv
NO20082269L (no) Nye piperaziner som antimalariamidler
BRPI0418099A (pt) compostos, composição farmacêutica, e uso de um composto
UY28271A1 (es) Compuestos químicos
BRPI0417833A (pt) novos derivados de benzofurano, os quais podem ser usados na profilaxia ou tratamento de distúrbios relacionados com o receptor 5-ht6
UY28366A1 (es) Compuestos químicos
BRPI0409884A (pt) compostos, composições farmacêuticas, método para o tratamento ou porfilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos
BRPI0409882A (pt) compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos
BRPI0411246A (pt) composto, uso do mesmo, composição farmacêutica, e, métodos para terapia contra dor em um animal de sangue quente e para a preparação de um composto
BRPI0414777A (pt) compostos, composições farmacêuticas, uso de um ou mais compostos, e, método de tratar um paciente que sofre de um distúrbio
BRPI0409818A (pt) compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2285 DE 21/10/2014.